Cargando…

The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries

BACKGROUND: The global COVID-19 pandemic is still ongoing, and cross-country and cross-period variation in COVID-19 age-adjusted case fatality rates (CFRs) has not been clarified. Here, we aimed to identify the country-specific effects of booster vaccination and other features that may affect hetero...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Cui, Wheelock, Åsa M., Zhang, Chutian, Ma, Jian, Dong, Kaixing, Pan, Jingxiang, Li, Zhichao, Liang, Wannian, Gao, Jing, Xu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151823/
https://www.ncbi.nlm.nih.gov/pubmed/37143970
http://dx.doi.org/10.3389/fpubh.2023.1150095
_version_ 1785035624470806528
author Zhou, Cui
Wheelock, Åsa M.
Zhang, Chutian
Ma, Jian
Dong, Kaixing
Pan, Jingxiang
Li, Zhichao
Liang, Wannian
Gao, Jing
Xu, Lei
author_facet Zhou, Cui
Wheelock, Åsa M.
Zhang, Chutian
Ma, Jian
Dong, Kaixing
Pan, Jingxiang
Li, Zhichao
Liang, Wannian
Gao, Jing
Xu, Lei
author_sort Zhou, Cui
collection PubMed
description BACKGROUND: The global COVID-19 pandemic is still ongoing, and cross-country and cross-period variation in COVID-19 age-adjusted case fatality rates (CFRs) has not been clarified. Here, we aimed to identify the country-specific effects of booster vaccination and other features that may affect heterogeneity in age-adjusted CFRs with a worldwide scope, and to predict the benefit of increasing booster vaccination rate on future CFR. METHOD: Cross-temporal and cross-country variations in CFR were identified in 32 countries using the latest available database, with multi-feature (vaccination coverage, demographic characteristics, disease burden, behavioral risks, environmental risks, health services and trust) using Extreme Gradient Boosting (XGBoost) algorithm and SHapley Additive exPlanations (SHAP). After that, country-specific risk features that affect age-adjusted CFRs were identified. The benefit of booster on age-adjusted CFR was simulated by increasing booster vaccination by 1–30% in each country. RESULTS: Overall COVID-19 age-adjusted CFRs across 32 countries ranged from 110 deaths per 100,000 cases to 5,112 deaths per 100,000 cases from February 4, 2020 to Jan 31, 2022, which were divided into countries with age-adjusted CFRs higher than the crude CFRs and countries with age-adjusted CFRs lower than the crude CFRs (n = 9 and n = 23) when compared with the crude CFR. The effect of booster vaccination on age-adjusted CFRs becomes more important from Alpha to Omicron period (importance scores: 0.03–0.23). The Omicron period model showed that the key risk factors for countries with higher age-adjusted CFR than crude CFR are low GDP per capita and low booster vaccination rates, while the key risk factors for countries with higher age-adjusted CFR than crude CFR were high dietary risks and low physical activity. Increasing booster vaccination rates by 7% would reduce CFRs in all countries with age-adjusted CFRs higher than the crude CFRs. CONCLUSION: Booster vaccination still plays an important role in reducing age-adjusted CFRs, while there are multidimensional concurrent risk factors and precise joint intervention strategies and preparations based on country-specific risks are also essential.
format Online
Article
Text
id pubmed-10151823
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101518232023-05-03 The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries Zhou, Cui Wheelock, Åsa M. Zhang, Chutian Ma, Jian Dong, Kaixing Pan, Jingxiang Li, Zhichao Liang, Wannian Gao, Jing Xu, Lei Front Public Health Public Health BACKGROUND: The global COVID-19 pandemic is still ongoing, and cross-country and cross-period variation in COVID-19 age-adjusted case fatality rates (CFRs) has not been clarified. Here, we aimed to identify the country-specific effects of booster vaccination and other features that may affect heterogeneity in age-adjusted CFRs with a worldwide scope, and to predict the benefit of increasing booster vaccination rate on future CFR. METHOD: Cross-temporal and cross-country variations in CFR were identified in 32 countries using the latest available database, with multi-feature (vaccination coverage, demographic characteristics, disease burden, behavioral risks, environmental risks, health services and trust) using Extreme Gradient Boosting (XGBoost) algorithm and SHapley Additive exPlanations (SHAP). After that, country-specific risk features that affect age-adjusted CFRs were identified. The benefit of booster on age-adjusted CFR was simulated by increasing booster vaccination by 1–30% in each country. RESULTS: Overall COVID-19 age-adjusted CFRs across 32 countries ranged from 110 deaths per 100,000 cases to 5,112 deaths per 100,000 cases from February 4, 2020 to Jan 31, 2022, which were divided into countries with age-adjusted CFRs higher than the crude CFRs and countries with age-adjusted CFRs lower than the crude CFRs (n = 9 and n = 23) when compared with the crude CFR. The effect of booster vaccination on age-adjusted CFRs becomes more important from Alpha to Omicron period (importance scores: 0.03–0.23). The Omicron period model showed that the key risk factors for countries with higher age-adjusted CFR than crude CFR are low GDP per capita and low booster vaccination rates, while the key risk factors for countries with higher age-adjusted CFR than crude CFR were high dietary risks and low physical activity. Increasing booster vaccination rates by 7% would reduce CFRs in all countries with age-adjusted CFRs higher than the crude CFRs. CONCLUSION: Booster vaccination still plays an important role in reducing age-adjusted CFRs, while there are multidimensional concurrent risk factors and precise joint intervention strategies and preparations based on country-specific risks are also essential. Frontiers Media S.A. 2023-04-18 /pmc/articles/PMC10151823/ /pubmed/37143970 http://dx.doi.org/10.3389/fpubh.2023.1150095 Text en Copyright © 2023 Zhou, Wheelock, Zhang, Ma, Dong, Pan, Li, Liang, Gao and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Zhou, Cui
Wheelock, Åsa M.
Zhang, Chutian
Ma, Jian
Dong, Kaixing
Pan, Jingxiang
Li, Zhichao
Liang, Wannian
Gao, Jing
Xu, Lei
The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries
title The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries
title_full The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries
title_fullStr The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries
title_full_unstemmed The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries
title_short The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries
title_sort role of booster vaccination in decreasing covid-19 age-adjusted case fatality rate: evidence from 32 countries
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151823/
https://www.ncbi.nlm.nih.gov/pubmed/37143970
http://dx.doi.org/10.3389/fpubh.2023.1150095
work_keys_str_mv AT zhoucui theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT wheelockasam theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT zhangchutian theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT majian theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT dongkaixing theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT panjingxiang theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT lizhichao theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT liangwannian theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT gaojing theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT xulei theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT zhoucui roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT wheelockasam roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT zhangchutian roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT majian roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT dongkaixing roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT panjingxiang roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT lizhichao roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT liangwannian roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT gaojing roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries
AT xulei roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries